EGFR and non-small cell lung carcinoma: The effectiveness of targeted liposomes co-loaded and conjugated with DNA biodots, etoposide, and cetuximab (CTXBD-ETP liposomes) in the treatment of advanced-stage non-small cell lung carcinoma (NSCLC) was demonstrated by Jha et al. Targeting EGFR in A549 lung cancer cells showed that the CTXBD-ETP liposomes displayed potent cytotoxic activity against these cells [77].